Regeneron Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 03/22/2023

Stock Rating
2
Price Target
$782.00
Consensus
Outperform
Upside
2.92%
Analysts
9
Stock Rating
2
Upside
2.92%
Analysts
9
Price Target
$782.00

Regeneron Pharmaceuticals Inc Stock Forecast and Price Target

The average target price for Regeneron Pharmaceuticals Inc's stock set by nine renowned analysts in recent months is $782.00, representing a potential upside of approximately 2.92% from its last closing price if met by 2024. This estimation is based on a high estimate of $1023.00 and a low estimate of $595.00. If you want to invest in REGN stock, you might also want to take a look at how its competitors are doing.

$782.00

2.92% Upside

Outperform
Outperform

Regeneron Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Regeneron Pharmaceuticals Inc's Price has seen an increase, rising from $311.34 to $942.21. This represents a growth of 202.63%. According to 22 major analysts, Regeneron Pharmaceuticals Inc's Fair Value will fall by 38.48% in the next year, reaching $579.64. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Fair Value will fall to $508.21– a 46.06% decrease from its current value.

2023 Fair Value Forecast
$579.64
2024 Fair Value Forecast
$601.85
2025 Fair Value Forecast
$600.59
2026 Fair Value Forecast
$587.21
2027 Fair Value Forecast
$557.68
2028 Fair Value Forecast
$527.14
2029 Fair Value Forecast
$516.28
2030 Fair Value Forecast
$508.21
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$153.96 $181.05 17.24%
LLY Stock Forecast Eli Lilly and Outperform 16
$331.08 $333.19 20.82%
PFE Stock Forecast Pfizer Inc Outperform 3
$40.66 $53.97 29.49%
MRK Stock Forecast Merck Outperform 5
$105.62 $99.57 11.72%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$67.52 $80.99 22.93%

Regeneron Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Regeneron Pharmaceuticals Inc's Revenue has seen an increase, rising from $6.56B to $16.07B. This represents a growth of 145.09%. According to 20 major analysts, Regeneron Pharmaceuticals Inc's Revenue will fall by 22.68% in the next year, reaching $12.43B. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Revenue will fall to $11.25B– a 29.98% decrease from its current value.

2023 Rev Forecast
$12.43B
2024 Rev Forecast
$12.85B
2025 Rev Forecast
$12.88B
2026 Rev Forecast
$12.82B
2027 Rev Forecast
$11.97B
2028 Rev Forecast
$11.70B
2029 Rev Forecast
$11.62B
2030 Rev Forecast
$11.25B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 16
$302.66 $323.74 7.71%
ZTS Stock Forecast Zoetis Outperform 18
$166.35 $209.70 23.23%
BAX Stock Forecast Baxter International Inc Outperform 17
$39.62 $60.73 46.39%

Regeneron Pharmaceuticals Inc Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$190.34 $244.18 31.87%
VTRS Stock Forecast Viatris Hold 8
$9.44 $13.70 43.01%
UTHR Stock Forecast United Therapeutics Outperform 12
$222.34 $280.69 32.68%

Regeneron Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

Regeneron Pharmaceuticals Inc's Free Cash Flow has grown in the last two years, jumping from $2.00B to $6.53B – an increase of 226.40%. In the following year, 5 experts forecast that Regeneron Pharmaceuticals Inc's Free Cash Flow will decrease by 14.74%, to $5.57B. In 2030, professionals predict that Regeneron Pharmaceuticals Inc's Free Cash Flow will decrease by 20.88%, to $5.17B.

2023 FCF Forecast
$5.57B
2024 FCF Forecast
$5.63B
2025 FCF Forecast
$5.70B
2026 FCF Forecast
$5.50B
2027 FCF Forecast
$5.38B
2028 FCF Forecast
$5.38B
2029 FCF Forecast
$5.26B
2030 FCF Forecast
$5.17B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$66.78 $83.92 9.31%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$35.62 $52.42 40.37%
CYTK Stock Forecast Cytokinetics Outperform 10
$36.17 $62.67 65.88%

Regeneron Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Net Income for Regeneron Pharmaceuticals Inc has grown by 281.67%, going from $2.12B to $8.08B. According to 18 analysts, Regeneron Pharmaceuticals Inc's Net Income will fall by 35.07% in the next year, reaching $5.24B. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Net Income will fall to $4.68B – a 42.02% decrease from its current value.

2023 NI Forecast
$5.24B
2024 NI Forecast
$5.45B
2025 NI Forecast
$5.43B
2026 NI Forecast
$5.36B
2027 NI Forecast
$5.06B
2028 NI Forecast
$4.82B
2029 NI Forecast
$4.74B
2030 NI Forecast
$4.68B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$127.30 $163.67 28.83%
NEOG Stock Forecast Neogen Hold 16
$18.91 $37.00 34.85%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$21.25 $0.00 38.82%

Regeneron Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Regeneron Pharmaceuticals Inc's EBITDA has increased by 276.04%, going from $2.46B to $9.23B. 6 analysts predict Regeneron Pharmaceuticals Inc's EBITDA will decrease by 28.65% in the next year, reaching $6.59B. By 2030, professionals predict that Regeneron Pharmaceuticals Inc's EBITDA will decrease by 35.39%, to $5.97B.

2023 EBITDA Forecast
$6.59B
2024 EBITDA Forecast
$7.12B
2025 EBITDA Forecast
$6.93B
2026 EBITDA Forecast
$6.98B
2027 EBITDA Forecast
$5.47B
2028 EBITDA Forecast
$5.62B
2029 EBITDA Forecast
$5.79B
2030 EBITDA Forecast
$5.97B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$14.91 $73.38 27.43%
INDV Stock Forecast Indivior PLC Buy 14
£179.50 £3.79 -97.36%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$40.28 $79.67 93.64%

Regeneron Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Regeneron Pharmaceuticals Inc's EBIT has grown, increasing from $2.25B to $8.95B – an increase of 298.52%. For the following year, the 5 analysts predict that Regeneron Pharmaceuticals Inc's EBIT will drop by 41.32%, reaching $5.25B. In 2030, the professionals' prediction is that REGN's EBIT will decrease by 50.53%, reaching $4.43B.

2023 EBIT Forecast
$5.25B
2024 EBIT Forecast
$5.27B
2025 EBIT Forecast
$5.62B
2026 EBIT Forecast
$6.90B
2027 EBIT Forecast
$6.84B
2028 EBIT Forecast
$4.67B
2029 EBIT Forecast
$4.27B
2030 EBIT Forecast
$4.43B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$36.99 $41.00 18.95%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$10.59 $12.60 18.04%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$36.70 $35.50 -7.36%

Regeneron Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Regeneron Pharmaceuticals Inc's EPS has seen an increase, rising from $24.67 to $74.66. This represents a growth of 202.63%. According to 22 major analysts, Regeneron Pharmaceuticals Inc's EPS will fall by 38.48% in the next year, reaching $45.93. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's EPS will fall to $40.27– a 46.06% decrease from its current value.

2023 EPS Forecast
$45.93
2024 EPS Forecast
$47.69
2025 EPS Forecast
$47.59
2026 EPS Forecast
$46.53
2027 EPS Forecast
$44.19
2028 EPS Forecast
$41.77
2029 EPS Forecast
$40.91
2030 EPS Forecast
$40.27
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$71.18 $195.43 122.67%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$245.62 $170.08 -28.75%
USNA Stock Forecast USANA Health Sciences Hold 14
$61.15 $104.00 -6.79%